The OncoAlert Newsletter is NOW OUT Click to Register
The OncoAlert Newsletter is now out for June 23-29, 2023
The OncoAlert Newsletter is now out for June 23-29, 2023
In this ARC Talks webinar for patients, Dr. Sharmila Dorbala explained the role that medical imaging techniques play in both diagnosing and managing amyloido…
The Future of Diagnostic Tests: New Data & Modern Policy4:41 – Welcoming Remarks8:57 – Opening Keynote (Jeff Shuren, Director, CDRH, U.S. FDA)35:17 – Sessi…
Cancer Cytopathology is an international cytopathology journal publishing research related to topics concerning the etiology of cancer, its diagnosis and prevention.
Uproleselan plus chemotherapy did not achieve a statistically significant improvement in OS vs chemotherapy alone in patients with relapsed/refractory AML.
More than one-fourth of cancer survivors reported having a physical disability that diminished their mobility, according to study results published in Journal of Clinical Oncology.Nearly…
The European Medicines Agency has validated an application for nivolumab plus ipilimumab for frontline MSI-H/dMMR metastatic colorectal cancer.
Learn about promising cancer treatments and donate to a cancer research charity to help with efforts to make every cancer patient a survivor.
The OncoAlert Newsletter is now out for June 23-29, 2023
Leland Metheny, MD, discusses how agents such as Iomab-B have potential to shift practice in the hematologic malignancy space.